Anavex Life Sciences Corp (AVXL)

[Doktornolittle]

The FDA set a precedent approving an ALZ drug with dubious efficacy, but asking for a confirmatory while the sponsor markets the drugs. In marketing and or in a confirmatory, Anavex would want to use DNA or RNA patient screening. They recently found that about 20% of patients are not good candidates for 273. Those patients deserve to know up front that they are not good candidates. Not ethical to sell to them. It's the right thing to do to let them move on. It also makes sense for a confirmatory even if not absolutely necessary. If Anavex did not state this up front, prior to a confirmatory, it would open them to criticism by the two Stooges. They stated it up front recently saying that any future trials will include this DNA or RNA patient screening, including any ALZ trials. It was apparently interpreted by some as foreshadowing of a failure. It might be, but more likely, in my opinion, it was stated for the reasons above.